I hereby certify that this correspond e is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: February 14, 2003

Signature M. M. M. DiRoccoi

Docket No.: CBN-002CP (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Patent Application of: Timothy A. Springer, et al

Application No.: 09/945265

Group Art Unit: 1644

Filed: August 31, 2001

Examiner: Maher M. Haddad

For: MODIFIED POLYPEPTIDES STABILIZED IN

A DESIRED CONFORMATION AND METHODS FOR PRODUCING SAME

MECEIVED

SUBMISSION OF FORMAL DRAWINGS

TECH CENTER 1600/2900

Commissioner for Patents Washington, DC 20231

Dear Sir:

Submitted herewith is one set (thirteen sheets, figures 1-12C) of formal drawings for filing in the above-identified patent application. Kindly substitute the enclosed formal drawings for the informal drawings submitted with the originally filed application.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. CBN-002CP from which the undersigned is authorized to draw.

Dated: February 14, 2003

Respectfully submitted

Lisa M. DiRocco

Registration No.: 51,619

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109


(617) 227-7400

(617) 742-4214 (Fax)

Attorney for Applicants















FIG.2D low affinity structure






FIG.2B high affinity model







FIG. 3A

FIG. 3B



Log Fluorescence Intensity

Log Fluorescence Intensity



FIG. 4A

293T transfectants

control

mAb CBRLFA-1/2

4/13




FIG. 4B

K562 transfectants

control

mAb CBRLFA-1/2






FIG. 4C



- Mg + Ca
- ☑ Mg
- Mn EDTA




FIG. 5



Log Fluorescence Intensity



FIG. 6




MOCK

WT/Mn WT/CBRLFA1/2 HA/aLb2



FIG. 7



Log Fluorescence Intensity



FIG. 8A




FIG. 8B





FIG. 8C




K287C/K294C I-domain (#1) intact LFA-1+CBRLFA-1/2



FIG. 9A

FIG. 9B



Time (S)





FIG. 9C








FIG. 9F






FIG. 10A






FIG. 10B



12/13

11A FIG.



11B FIG.





FIG. 11C



□ CBRM1/32 ■ CBRM1/5

L15/Mn L15/Mn/CBRM1/5

PATENT & TRIPLE

13/13

FIG. 12A




FIG. 12B





FIG. 12C



⊐ L15/Mn

■ L15/Mn/CBRM1/5

L15/Mn/DTT